Lexaria Bioscience Corp. (LEXX)

Market Cap	14.58M -2.2%
Revenue (ttm)	194,000 -68.5%
Net Income	-7.73M
EPS	-0.34
Shares Out	24.79M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	18,156
Open	0.6090
Previous Close	0.5872
Day's Range	0.5630 - 0.6100
52-Week Range	0.4600 - 1.5500
Beta	0.34
Analysts	n/a
Price Target	n/a
Earnings Date	Jul 13, 2026

About LEXX

Lexaria Bioscience Corp. operates as a biotechnology company. The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. Its DehydraTECH is used with a range of active molecules, including ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 7
• Stock Exchange: NASDAQ
• Ticker Symbol: LEXX
• Website: https://lexariabioscience.com

Financial Performance

In fiscal year 2025, Lexaria Bioscience's revenue was $705,923, an increase of 52.05% compared to the previous year's $464,278. Losses were -$11.90 million, 105.4% more than in 2024.

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Jul 15, 2026

Data Sources Report a data error